ANGICYTE
LIVE

Serial Number

79399244

Owner

VASCVERSA LIMITED

Attorney

Usha Menon

Filing Date

Mar 4, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ANGICYTE Trademark

Serial Number: 79399244 • Registration: 7838997

ANGICYTE is a trademark filed by VASCVERSA LIMITED on March 4, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

VASCVERSA LIMITED (2 trademarks)

63 University Road,

Entity Type: 24

Trademark Details

Filing Date

March 4, 2024

Registration Date

June 24, 2025

Published for Opposition

May 6, 2025

Goods & Services

Pharmaceutical preparations for the treatment of ischemic diseases; Drugs for medical purposes, namely, pharmaceutical preparations for the treatment of ischemic diseases; Pharmaceutical preparations containing stem cells for the treatment of ischemic diseases and stimulation of vascular regeneration, blood vessel repair, and tissue revitalization; Stem cells for medical purposes; cells for medical use; cell growth media for growing cells for medical use; living cells for medical use; cellular function activating agents for medical purposes; Vaccines; Reagents for medical use; medical diagnostic reagents

Medical devices for the treatment of ischemic diseases and stimulation of vascular regeneration, blood vessel repair, and tissue revitalization; Medical apparatus and instruments for the treatment of ischemic diseases and stimulation of vascular regeneration, blood vessel repair, and tissue revitalization; Apparatus for the regeneration of stem cells for medical purposes; medical devices and apparatus for vascular regeneration and repair in the treatment of ischemic diseases; Medical devices and apparatus for cell therapy for the treatment of ischemic diseases and stimulation of vascular regeneration, blood vessel repair, and tissue revitalization; Blood testing apparatus

Medical and pharmacological research services; Stem cell research; Scientific research services for others relating to the isolation and cultivation of human tissues and cells; Research in the field of cell engineering technology; Scientific and medical research in the field of vascular regeneration and repair; Research and development of medicines; Pharmaceutical drug development services; Drug discovery services; Development of pharmaceutical preparations and medicines; Development of stem and progenitor cell therapies and other cell therapies; Research and development services in the medical field of cell therapy; research and development services in the medical field of vascular regeneration and repair; Scientific research in the nature of conducting clinical trials for others; Blood analysis services for scientific research purposes

Stem cells for research purposes; stem cells for scientific purposes; chemicals for use in manufacturing pharmaceuticals; reagents for research purposes; reagents for medical research; reagents for scientific purposes; diagnostic reagents for scientific or research use; cell culture reagents for scientific and research use; blood culture media for scientific use

Regenerative medicine services; medical services; stem cell therapy services; cell therapy services; Stem cell therapy services for vascular regeneration and repair; cell therapy services relating to the generation of human vascular reparative cells; cell therapy services relating to the injecting, grafting or implanting of cells into patients; medical services relating to the removal, treatment and processing of cells; Medical services relating to the removal, treatment and processing of stem cells; Stem cell storage, namely, stem cell bank services; Cultured cell bank services for medical transplantation; medical laboratory services for the analysis of samples taken from patients; Medical analysis services for the diagnosis and treatment of persons; Services for the testing of blood, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical services relating to the removal, treatment and processing of human blood

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 12, 2026 FINO
NEW REPRESENTATIVE AT IB RECEIVED
Feb 19, 2026 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Feb 5, 2026 NREP
FINAL DISPOSITION NOTICE SENT TO IB
Jan 21, 2026 FICS
FINAL DISPOSITION PROCESSED
Jan 21, 2026 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 18, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 3, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 3, 2025 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 24, 2025 FICR
NEW REPRESENTATIVE AT IB RECEIVED
Jul 11, 2025 NREP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 24, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 24, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 6, 2025 NPUB
PUBLISHED FOR OPPOSITION
May 6, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 30, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 7, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 13, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 13, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 13, 2025 TROA
REFUSAL PROCESSED BY IB
Oct 12, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 21, 2024 RFCS
REFUSAL PROCESSED BY MPU
Sep 20, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 19, 2024 RFCR
NON-FINAL ACTION WRITTEN
Sep 18, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 18, 2024 DOCK
ASSIGNED TO EXAMINER
Sep 18, 2024 DOCK
ASSIGNED TO EXAMINER
Sep 18, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 11, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 11, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 4, 2024 REPR